Designing a novel drug–drug conjugate as a prodrug for breast cancer therapy: in silico insights
Molecular Diversity · 2025
DOI: 10.1007/s11030-024-10886-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Diversity, 2025. Verfasst von Sankar Muthumanickam und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioinformatics, Alagappa University, Karaikudi, Tamil Nadu, India. Hauptthemen laut MEDLINE: Prodrugs, Breast Neoplasms, Drug Design, Antineoplastic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 57 Literaturangaben.
Abstract (Originalsprache)
Breast cancer (BC) poses a significant global health threat, necessitating innovative therapeutic approaches. The ribosomal s6 kinase 2 (RSK2) has emerged as a promising target due to its roles in cell proliferation and survival. This study proposes a drug-drug conjugate prodrug comprising Methotrexate (hydrophobic) and Capecitabine (hydrophilic) for BC treatment. In silico approaches, including Molecular Docking, Molecular Dynamics Simulations, MM-PBSA, ADME, and DFT calculations were employed to evaluate the prodrug's potential. The designed MET-CAP ligand exhibits a robust docking score (-8.980 kcal/mol), superior binding affinity (-53.16 kcal/mol), and stable dynamic behavior (0.62 nm) compared to native ligands. The DFT results reveal intramolecular charge transfer in MET-CAP (HLG = 0.09 eV), indicating its potential as a BC inhibitor. ADME analysis suggests satisfactory pharmaceutically relevant properties. The results indicate that the conjugated MET-CAP ligand exhibits favorable binding characteristics, stability, and pharmaceutically relevant properties, making it a potential RSK2 inhibitor for BC therapy. The multifaceted approach provides insights into binding interactions, stability, and pharmacokinetic properties, laying the foundation for further experimental validation and potential clinical development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bioinformatics, Alagappa University, Karaikudi, Tamil Nadu, India.
- Department of Pharmacology, Saveetha Institute of Technical and Medical Sciences (SIMATS), Chennai, 600 077, India.
- Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN, 46556, USA.
- BiOMe Live Analytical Research Centre, Karaikudi, Tamil Nadu, India.
- Department of Bioinformatics, Alagappa University, Karaikudi, Tamil Nadu, India. pboomi1983@gmail.com.
Zitieren
APA
Muthumanickam, S., Ramachandran, B., Jeyakanthan, J., Jegatheswaran, S., & Pandi, B. (2025). Designing a novel drug–drug conjugate as a prodrug for breast cancer therapy: in silico insights. Molecular Diversity. https://doi.org/10.1007/s11030-024-10886-w
Vancouver
Muthumanickam S, Ramachandran B, Jeyakanthan J, Jegatheswaran S, Pandi B. Designing a novel drug–drug conjugate as a prodrug for breast cancer therapy: in silico insights. Molecular Diversity. 2025. doi:10.1007/s11030-024-10886-w
BibTeX
@article{Muthumanickam2025,
author = {Muthumanickam, Sankar and Ramachandran, Balajee and Jeyakanthan, Jeyaraman and Jegatheswaran, Sonamuthu and Pandi, Boomi},
title = {Designing a novel drug–drug conjugate as a prodrug for breast cancer therapy: in silico insights},
journal = {Molecular Diversity},
year = {2025},
doi = {10.1007/s11030-024-10886-w}
}
EUVIMED